- Home
- JANX vs CASH Comparison
JANX vs CASH Comparison
Compare JANX & CASH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JANX
- CASH
- Stock Information
- Founded
- JANX 2017
- CASH 1954
- Country
- JANX United States
- CASH United States
- Employees
- JANX N/A
- CASH N/A
- Industry
- JANX Biotechnology: Pharmaceutical Preparations
- CASH Major Banks
- Sector
- JANX Health Care
- CASH Finance
- Exchange
- JANX Nasdaq
- CASH Nasdaq
- Market Cap
- JANX 1.6B
- CASH 1.7B
- IPO Year
- JANX 2021
- CASH N/A
- Fundamental
- Price
- JANX $31.05
- CASH $78.96
- Analyst Decision
- JANX Strong Buy
- CASH Buy
- Analyst Count
- JANX 7
- CASH 2
- Target Price
- JANX $94.29
- CASH $92.00
- AVG Volume (30 Days)
- JANX 975.8K
- CASH 263.2K
- Earning Date
- JANX 05-06-2025
- CASH 04-22-2025
- Dividend Yield
- JANX N/A
- CASH 0.25%
- EPS Growth
- JANX N/A
- CASH 10.71
- EPS
- JANX N/A
- CASH 7.36
- Revenue
- JANX $10,588,000.00
- CASH $731,383,000.00
- Revenue This Year
- JANX N/A
- CASH $14.27
- Revenue Next Year
- JANX $250.58
- CASH $6.20
- P/E Ratio
- JANX N/A
- CASH $10.73
- Revenue Growth
- JANX 30.99
- CASH 6.51
- 52 Week Low
- JANX $22.52
- CASH $50.00
- 52 Week High
- JANX $71.71
- CASH $86.00
- Technical
- Relative Strength Index (RSI)
- JANX 55.36
- CASH 66.35
- Support Level
- JANX $27.93
- CASH $69.32
- Resistance Level
- JANX $32.59
- CASH $81.82
- Average True Range (ATR)
- JANX 1.97
- CASH 3.17
- MACD
- JANX 0.74
- CASH 1.34
- Stochastic Oscillator
- JANX 84.75
- CASH 83.53
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
About CASH Pathward Financial Inc.
Pathward Financial Inc is a unitary savings and loan holding company. It's a wholly owned full-service banking subsidiary of Meta Financial, is both a community-oriented financial institution offering a variety of financial services to meet the needs of the communities it serves, and a payments company providing services on a nationwide basis. It operates through three reportable segments: Consumer: The Consumer segment includes the Partner Solutions business line, which collaborates with partners to navigate payment and lending needs; Commercial: The Commercial segment includes the Company's Commercial Finance business line, which helps businesses access funds needed to launch, operate, and grow; and Corporate Services. The majority of the revenue is generated from Consumer segment.